Hathal Haddad, Head of Interventional Radiotherapy Unit at the Department of Radiation Oncology at University Hospital Tübingen, shared a post on LinkedIn about a recent article by Adrian Brunt et al., published in The Lancet Oncology:
“A New Era in Breast Cancer Radiotherapy: 10-Years FAST-Forward Results Changing Global Practice!
The updated 10-years results of the FAST-Forward trial confirm that 1-week hypofractionated breast radiotherapy is safe, effective, and non-inferior compared to the traditional 3-week schedule for early breast cancer treatment.
Key highlights:
- 4087 patients included with median follow-up of 10.1 years
- 26 Gy in 5 fractions over 1 week non-inferior to 40 Gy in 15 fractions over 3 weeks
- Lowest 10-years ipsilateral breast recurrence seen in the 26 Gy arm (2.1% vs 3.6% in standard arm)
- Acceptable late normal tissue effects: 14.4% in 26 Gy arm vs 13.1% in standard arm
- Reduced treatment burden, fewer hospital visits, and improved patient convenience
- Axillary substudy included 466 patients with promising 7-year locoregional control data
This landmark phase III trial continues to shape modern breast cancer radiotherapy practice worldwide and highlights how evidence-based hypofractionation can improve both efficiency and quality of care.
Congratulations to all investigators and participating centers for this important contribution to radiation oncology.”
Title: Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
Authors: Adrian Brunt, Fay Cafferty, Anna Kirby, Jaymini Patel, Mark Sydenham, Joanne Haviland, Susan Griffin, Carlos Chivardi, Helen Fleming, Charlotte Coles, David Bloomfield, Charlie Chan, Susan Cleator, Andy Goodman, Clare Griffin, Cliona Kirwan, Zohal Nabi, Elinor Sawyer, Navita Somaiah, Isabel Syndikus, Karen Venables, Duncan Wheatley, John Yarnold, Judith Bliss
Read the Full Article on The Lancet Oncology.
More posts featuring Hathal Haddad.
